BioCradle Artificial Placenta System: Letting Extremely Preterm Infants Continue Developing Outside the Womb

BioCradle Artificial Placenta System: Letting Extremely Preterm Infants Continue Developing Outside the Womb

A joint team from the Children's Hospital of Philadelphia (CHOP) and Maastricht University Medical Center has published results from the first clinical trial of the BioCradle artificial placenta system in the New England Journal of Medicine. Designed for infants born before 26 weeks of gestation, BioCradle lets babies complete critical developmental stages in an extra-uterine environment.

BioCradle's core is a sealed chamber filled with synthetic amniotic fluid. The infant's head remains outside the chamber so clinicians can monitor vital signs. The fluid uses a special formulation containing every growth factor and nutrient required for fetal development. The baby's umbilical vessels are connected to an extracorporeal membrane oxygenation system that mimics the maternal placenta's gas exchange, nutrient delivery, and waste removal functions.

The first trial enrolled eight extremely preterm infants born between 25 and 26 weeks. These babies survived an average of 37 days inside BioCradle, with the longest-running case transferred to a conventional neonatal intensive care unit after 112 days. Six of the eight ultimately survived — a 75 percent rate, well above the approximately 45 percent survival seen with standard care at that gestational age.

The key technical breakthrough is the biocompatibility of the oxygenation membrane. Conventional ECMO membranes trigger inflammatory reactions after extended blood contact, which limits how long they can be used. The BioCradle team developed a bio-hybrid membrane seeded with endothelial cells cultured from each infant's own cord blood. That cell layer substantially reduces the risk of clotting and inflammation.

Luc Zimmermann, director of neonatology at Maastricht University Medical Center and a co-lead of the study, wrote in the paper's discussion that BioCradle represents a fundamental shift in NICU care — from supporting an infant's adaptation to the outside world to recreating the intrauterine environment so development can proceed at its natural pace. The clinical significance, he argued, lies not only in higher survival but also in reducing the incidence of prematurity-related complications such as cerebral palsy and retinopathy of prematurity.

Ethically, the study underwent rigorous review by the IRBs at CHOP and Maastricht UMC. Every family went through an exhaustive informed-consent process, including on-site demonstrations of the BioCradle system, tours of the research facility, and multiple rounds of conversations with the research team.

The researchers acknowledge that the technology remains at an early stage. BioCradle currently supports continuous operation for roughly four months, corresponding to a maximum gestational age of about 30 weeks. That ceiling reflects the durability of the bio-hybrid membrane — the endothelial cells seeded on its surface gradually lose function during long-term ex vivo culture. The team is developing a next-generation membrane aimed at extending support to more than six months.

On the commercialization path, CHOP has partnered with medical device company Medtronic to develop a commercial version. Medtronic plans to submit a pre-market approval application to the FDA in 2027, with launch expected in 2028 at 15 tertiary hospitals in the United States and European Union. Medtronic chief medical officer Laura Maurer said R&D investment in BioCradle has already exceeded $140 million, and the company is working to keep pricing within reach for ordinary families.

Some neonatologists have expressed caution about BioCradle's rapid advance. Dr. Priscilla Chan, head of neonatology at Toronto's Mount Sinai Hospital, said more clinical data are needed to confirm the system does not introduce unexpected long-term complications. She recommended at least five years of follow-up research before expanding indications.